• Teva Pharmaceutical Industries Ltd., of Jerusalem, presented Phase IIa data for laquinimod in Crohn's disease showing treatment with laquinimod 0.5 mg/day gave a remission rate of 48.3 percent, compared to 15.9 percent for patients receiving placebo.